Compare

Compare stocks side by side

Pick up to 3 companies to see where each one is stronger or weaker.

ALLOATNM

Allogene Therapeutics, Inc.

ALLO · $1.25

41Weak

Actinium Pharmaceuticals, Inc.

ATNM · $1.53

80Strong

Area by area

Overall Quant Score

How does it look overall? (out of 100)

ALLO

41/100

ATNM

80/100

Quality

Is it a profitable, well-run business?

ALLO

2.0/10

ATNM

9.5/10

Growth

Is the company growing?

ALLO

5.3/10

ATNM

5.9/10

Valuation

Is the price reasonable? (higher = cheaper)

ALLO

0.0/10

ATNM

8.8/10

Risk

How risky are the shares? (higher = lower risk)

ALLO

5.0/10

ATNM

5.0/10

Momentum

Is the share price trending up?

ALLO

3.6/10

ATNM

9.5/10

Financial strength

Is the balance sheet healthy?

ALLO

4.6/10

ATNM

5.8/10

The balanced view

Model-generated

Allogene Therapeutics, Inc.

This company scores below average, with supportive analyst views, although its current valuation deserves attention.

Leads on: risk

Best feature: analysts broadly positive (Target upside: 2022.4%)

Watch out: valuation may be demanding (P/E (TTM): -1.9x)

Actinium Pharmaceuticals, Inc.

This company scores well across most areas, with supportive analyst views and a positive price trend.

Leads on: quality, growth, valuation, risk, momentum, financial strength

Best feature: analysts broadly positive (Analyst buy share: 100%)

Watch out: weakest area: risk profile (Price volatility (1Y, annualised): 71%)

Different strengths suit different goals — a higher score in one area doesn’t make a stock the better choice for everyone.